Femasys Inc.

Femasys Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.

Company Details

Employees
61
Address
3950 Johns Creek Ct,
Phone
1(770) 500-3910
Email
cu****@****sys.com
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Suwanee, Georgia
Looking for a particular Femasys Inc. employee's phone or email?

Femasys Inc. Questions

News

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe - Yahoo Finance

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe Yahoo Finance

Femasys (NASDAQ: FEMY) starts FemBloc post-market study under EU MDR and ethics approvals - Stock Titan

Femasys (NASDAQ: FEMY) starts FemBloc post-market study under EU MDR and ethics approvals Stock Titan

Femasys Inc. to Showcase Innovative Fertility Solutions at ASRM 2025 Scientific Congress & Expo - Quiver Quantitative

Femasys Inc. to Showcase Innovative Fertility Solutions at ASRM 2025 Scientific Congress & Expo Quiver Quantitative

Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios - Yahoo Finance

Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios Yahoo Finance

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - Stock Titan

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo Stock Titan

Femasys Inc. Partners with Kebomed to Expand FemBloc Permanent Birth Control Availability in France and Benelux Region - Quiver Quantitative

Femasys Inc. Partners with Kebomed to Expand FemBloc Permanent Birth Control Availability in France and Benelux Region Quiver Quantitative

Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership - GlobeNewswire

Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership GlobeNewswire

Femasys Expands FemSperm™ Product Line with New - GlobeNewswire

Femasys Expands FemSperm™ Product Line with New GlobeNewswire

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - GlobeNewswire

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering GlobeNewswire

Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed - GlobeNewswire

Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed GlobeNewswire

Femasys Announces Second Quarter Financial Results for 2025 - GlobeNewswire

Femasys Announces Second Quarter Financial Results for 2025 GlobeNewswire

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion - GlobeNewswire

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion GlobeNewswire

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth - GlobeNewswire

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth GlobeNewswire

Femasys Inc. Receives MEDSAFE Approval for FemBloc Permanent Birth Control in New Zealand, Expanding Global Access to Innovative Women's Health Solutions - Quiver Quantitative

Femasys Inc. Receives MEDSAFE Approval for FemBloc Permanent Birth Control in New Zealand, Expanding Global Access to Innovative Women's Health Solutions Quiver Quantitative

First Non-Surgical Permanent Birth Control: Femasys' FemBloc Launches Major European Expansion - Stock Titan

First Non-Surgical Permanent Birth Control: Femasys' FemBloc Launches Major European Expansion Stock Titan

Femasys Closes $8 Million in Financing - citybiz

Femasys Closes $8 Million in Financing citybiz

Non-Surgical Birth Control Pioneer Femasys Lands $8M to Scale Revolutionary Women's Health Solutions - Stock Titan

Non-Surgical Birth Control Pioneer Femasys Lands $8M to Scale Revolutionary Women's Health Solutions Stock Titan

Femasys Announces Pricing of Underwritten Public Offering - GlobeNewswire

Femasys Announces Pricing of Underwritten Public Offering GlobeNewswire

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones - ts2.tech

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones ts2.tech

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement - GlobeNewswire

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement GlobeNewswire

First Non-Surgical Permanent Birth Control: Femasys FemBloc Gets UK Green Light After CE Mark - Stock Titan

First Non-Surgical Permanent Birth Control: Femasys FemBloc Gets UK Green Light After CE Mark Stock Titan

Femasys Inc. Announces Regulatory Progress and Financial Results for First Quarter 2025 in Women's Health Innovation - Nasdaq

Femasys Inc. Announces Regulatory Progress and Financial Results for First Quarter 2025 in Women's Health Innovation Nasdaq

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update - GlobeNewswire

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update GlobeNewswire

Femasys Inc. Achieves Key Regulatory Approvals and Financial Growth in Fertility Portfolio for Q2 2025 - Quiver Quantitative

Femasys Inc. Achieves Key Regulatory Approvals and Financial Growth in Fertility Portfolio for Q2 2025 Quiver Quantitative

Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations - GlobeNewswire

Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations GlobeNewswire

Femasys Inc. Launches FemBloc Permanent Contraceptive in Spain, Pioneering Access to Non-Surgical Birth Control in Europe | FEMY Stock News - Quiver Quantitative

Femasys Inc. Launches FemBloc Permanent Contraceptive in Spain, Pioneering Access to Non-Surgical Birth Control in Europe | FEMY Stock News Quiver Quantitative

First-Ever Non-Surgical Permanent Birth Control: Femasys FemBloc Approved in New Zealand Market - Stock Titan

First-Ever Non-Surgical Permanent Birth Control: Femasys FemBloc Approved in New Zealand Market Stock Titan

2X Higher Pregnancy Rates: Femasys Expands FemSperm Line for Revolutionary FemaSeed Fertility Treatment - Stock Titan

2X Higher Pregnancy Rates: Femasys Expands FemSperm Line for Revolutionary FemaSeed Fertility Treatment Stock Titan

2X Higher Pregnancy Rates: Femasys Launches Groundbreaking In-Office Fertility Kit for Gynecologists - Stock Titan

2X Higher Pregnancy Rates: Femasys Launches Groundbreaking In-Office Fertility Kit for Gynecologists Stock Titan

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge? - ts2.tech

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge? ts2.tech

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain - GlobeNewswire

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain GlobeNewswire

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update - GlobeNewswire

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update GlobeNewswire

Femasys Announces FemBloc Delivery System Approval in - GlobeNewswire

Femasys Announces FemBloc Delivery System Approval in GlobeNewswire

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations - GlobeNewswire

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations GlobeNewswire

Women's Health Innovator Femasys Secures $4.5M Strategic Financing to Accelerate Commercial Growth - Stock Titan

Women's Health Innovator Femasys Secures $4.5M Strategic Financing to Accelerate Commercial Growth Stock Titan

Revolutionary Birth Control Breakthrough: Europe Approves First-Ever Non-Surgical Permanent Solution - Stock Titan

Revolutionary Birth Control Breakthrough: Europe Approves First-Ever Non-Surgical Permanent Solution Stock Titan

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials - Yahoo Finance

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials Yahoo Finance

Femasys Announces Israeli Regulatory Approvals for - GlobeNewswire

Femasys Announces Israeli Regulatory Approvals for GlobeNewswire

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech - Yahoo Finance

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech Yahoo Finance

Femasys Inc. Receives U.S. FDA Clearance to Market - GlobeNewswire

Femasys Inc. Receives U.S. FDA Clearance to Market GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women - Yahoo Finance

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women Yahoo Finance

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution - Yahoo Finance

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution Yahoo Finance

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women - Yahoo Finance

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women Yahoo Finance

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada - Yahoo Finance

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada Yahoo Finance

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device - GlobeNewswire

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device GlobeNewswire

Femasys Inc. Announces Pricing of Initial Public Offering - GlobeNewswire

Femasys Inc. Announces Pricing of Initial Public Offering GlobeNewswire

Femasys Appoints Anne Morrissey to Board - citybiz

Femasys Appoints Anne Morrissey to Board citybiz

Oklahoma City News - The Oklahoman - FinancialContent

Oklahoma City News - The Oklahoman FinancialContent

Femasys Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference - PR Newswire

Femasys Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire

Top Femasys Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant